key: cord-0849480-55jxwr3y authors: Tan, Eng-King; Albanese, Alberto; Chaudhuri, KRay; Lim, Shen-Yang; Oey, Nicodemus Edrick; Shan Chan, Christine Hui; Wu, Yun-Cheng; Jeon, Beomseok; Truong, Daniel; Poewe, Werner; Pal, Pramod Kumar; Tan, Louis; Opal, Puneet; Colosimo, Carlo; Jinnah, H.A.; Cardoso, Francisco title: Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience date: 2020-10-07 journal: Parkinsonism Relat Disord DOI: 10.1016/j.parkreldis.2020.10.009 sha: 437d48b20ffe1697ba97dbdead85810e719fd2c3 doc_id: 849480 cord_uid: 55jxwr3y • The effects of COVID-19 are tangible on the clinical research front in PD and must be recognized. • Country-specific restrictions may pose challenges to PD research which will require adaptations by the scientific community. • Data interpretation in any PD clinical study has to be handled cautiously as neurological symptoms of COVID-19 may overlap with PD. With more than 30 million confirmed cases and almost a million deaths, COVID-19 is 108 redefining the way clinical research is being conducted around the world. Lifting of lockdown 109 measures when community spread appeared to have abated has led to resurgence of new 110 clusters, resulting in prompt reinstitution of restrictions such as that experienced in Korea, 111 China, Italy, India, and certain cities in Brazil and the USA. This dynamic back and forth 112 curtailment will likely go on until an effective treatment or vaccine is widely available, 113 necessitating novel adaptations for researchers to continue to thrive worldwide. 114 For patients with Parkinson's disease (PD), COVID-19 brings forth specific 115 challenges: first, hospitalised PD patients infected with COVID-19 have a higher mortality 116 compared to historic data of hospitalised PD patients in general [1] . Second, PD patients in 117 advanced stages are at a higher risk for pulmonary decompensation [2] . Third, PD patients 118 infected with COVID-19 reported worsening of both motor and non-motor symptoms, 119 requiring medication titration in about 30% of the cases [3]. Fourth, these patients 120 experienced more psychological symptoms and reported poorer quality of life measures 121 such as in measures of anxiety, which is also seen in 60% of their caregivers [4] . Fifth, 122 physical symptoms of PD and COVID-19 such as hyposmia and dysgeusia may overlap, 123 influencing clinical outcomes [5] . Lastly, though general knowledge of COVID-19 exists, 124 more than 80% of PD and 85% of their caregivers do not think there is an association 125 between COVID-19 and PD though a small percentage think there is a higher risk of PD 126 patients contracting COVID-19 [6] . 127 In the face of these challenges, how can we better adapt and implement solutions for 128 clinical research in PD after taking into consideration the community spread and the 129 infrastructure, governance, resources, and priority of individual institutions? Here we share 130 our views and learning experiences in the hope of offering solutions that may potentially help 131 others prepare and adapt to their individual situations depending on the extent of the local 132 community spread. 133 J o u r n a l P r e -p r o o f The common constraints imposed by the pandemic which may affect the integrity of 134 PD and other clinical studies included delays in study enrolment, staffing changes, hiring 135 freezes, coordinator furloughs, limited clinic space, remote interactions due to social 136 distancing measures, manpower shortages due to redeployment of staff to COVID-19-137 related roles, lack of training to handle infectious disease protocols, and lack of financial 138 support. These challenges and their possible solutions are listed in Table 1 . However, while 139 principles in maintaining trial integrity during the COVID-19 pandemic have been proposed 140 [7], they may be challenging for investigators to execute due to the varied nature of clinical 141 Specific country-to-country restrictions and challenges may differ, and these are 143 highlighted in Table 2 Retraining clinical and research staff on differentiating between COVID-19 symptoms and PD symptoms Case-by-case judgment based on clinical priority and COVID-19 disease burden in the area • National policies allow resuming of clinical trials including PD • Regional health authorities provide further regulation and hospital authorities define procedures • Hospitals limit access to caregivers aiming to reduce overcrowding • Telehealth is allowed for clinical studies, but teleprescription is not recognized by law India -COVID-19 cases are still increasing • Hospitals are primarily focusing on management of COVID-19 patients • Patients with PD are discouraged to visit hospitals unless an emergency arises • Many patients prefer telemedicine which many hospitals and private practitioners are providing • Hospital admission mandate COVID-19 testing • Clinical studies in PD have been halted indefinitely (at time of writing) due to lack of staff, patients, insurance and funding, lack of dedicated space and also quarantine issues • Government advisory is to temporarily cut down any new research staff recruitment except for essential services • Funding for existing research projects have been withheld in most places • COVID-19 related research to be given priority USA • Policies and procedures vary by state, and even between institutions in a single state • Some areas remain in lockdown for all but "essential" research, while others may continue many research activities • The use of telehealth technology is complicated by statedependent licensing, making it illegal for an investigator or clinician to conduct certain activities with research • Mild to moderate COVID-19 may be contracted independently of age and PD duration • COVID-19 induces worsening motor and nonmotor symptoms of PD • Motor symptoms include levodopa-responsive symptoms and increased off time, potentially due to inflammatory response and/or pharmacokinetics • Non-motor symptoms include increased fatigue, but not cognitive dysfunction or autonomic failure. Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic • PD patients showed worse stress, depression, and anxiety levels relative to pre-lockdown levels • PD patients had a decline in physical activity as measured by the International Physical Activity Questionnaire (IPAQ) scores, which correlated negatively with the Depression, Anxiety, and Stress Scale (DASS) 7) Salari Phenomenology and 274 outcomes of in-patients with Parkinson's disease during COVID-19 pandemic COVID-19 in Parkinson's Disease Patients Living in Lombardy Effects of COVID-19 on Parkinson's Disease Clinical Features: A 281 Community-Based Case-Control Study Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic Outcome of Parkinson's Disease Patients 286 Affected by COVID-19 Parkinson's Disease and COVID-19: Perceptions and Implications in Patients and 289 Conducting Clinical Research During the COVID-19 291 Pandemic: Protecting Scientific Integrity Parkinson's Disease and Movement Disorders The Coronavirus Disease 2019 Crisis as Catalyst 297 for Telemedicine for Chronic Neurological Disorders Effect of Virtual Reality on With Parkinson Disease: A Systematic Review and Meta-Analysis of Randomized Controlled 301 Trials Management of Advanced Therapies in Parkinson's Disease Patients 304 in Times of Humanitarian Crisis: The COVID-19 Experience 307 Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease Beyond the data: Understanding the impact of COVID-19 on BAME groups